Table 2.
Patient Demographics.
| Variables | Category | Total (n = 402) | Alive (n = 94) | Death (n = 308) | p-Value |
|---|---|---|---|---|---|
| Age | Mean (STD) | 63 (15.3) | 63.1 (13.4) | 63 (15.9) | |
| Sex | Female | 123 (30.6%) | 33 (35.1%) | 90 (29.2%) | |
| Male | 279 (69.4%) | 61 (64.9%) | 218 (70.8%) | ||
| ECOG | 0–1 | 255 (63.4%) | 86 (91.5%) | 169 (54.9%) | <0.0001 |
| 2+ | 147 (36.6%) | 8 (8.5%) | 139 (45.1%) | ||
| Melanoma stage | Stage III | 80 (19.9%) | 44 (46.8%) | 36 (11.7%) | <0.0001 |
| Stage IV | 322 (80.1%) | 50 (53.2%) | 272 (88.3%) | ||
|
BRAF mutation |
Mutant | 100 (24.9%) | 39 (41.5%) | 61 (19.8%) | <0.0001 |
| Wild | 165 (41%) | 41 (43.6%) | 124 (40.3%) | ||
| Unknown | 137 (34.1%) | 14 (14.9%) | 123 (39.9%) | ||
| LDH | LDH high | 140 (34.8%) | 6 (6.4%) | 134 (43.5%) | <0.0001 |
| LDH not high | 166 (41.3%) | 66 (70.2%) | 100 (32.5%) | ||
| Unknown | 96 (23.9%) | 22 (23.4%) | 74 (24%) |